About Centessa Pharmaceuticals plc
https://www.centessa.comCentessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients.
CEO
Saurabh Saha
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 16
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
B. Riley Securities
Buy
Guggenheim
Buy
Chardan Capital
Buy
Oppenheimer
Outperform
Wells Fargo
Overweight
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
MEDICXI VENTURES MANAGEMENT (JERSEY) LTD
Shares:19.96M
Value:$440.99M
AVORO CAPITAL ADVISORS LLC
Shares:10.81M
Value:$238.75M
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:10.04M
Value:$221.67M
Summary
Showing Top 3 of 131
About Centessa Pharmaceuticals plc
https://www.centessa.comCentessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $53.79M ▼ | $-54.89M ▼ | 0% | $-0.41 ▼ | $-51.6M ▼ |
| Q2-2025 | $0 ▼ | $54.65M ▲ | $-50.34M ▼ | 0% ▲ | $-0.38 ▼ | $-46.45M ▼ |
| Q1-2025 | $15M ▲ | $45.78M ▼ | $-26.14M ▲ | -174.23% ▼ | $-0.2 ▲ | $-21.64M ▲ |
| Q4-2024 | $0 | $74.58M ▲ | $-111.33M ▼ | 0% | $-0.84 ▼ | $-107.57M ▼ |
| Q3-2024 | $0 | $46.41M | $-42.57M | 0% | $-0.37 | $-39.16M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $246.21M ▼ | $448.3M ▼ | $146.73M ▼ | $301.57M ▼ |
| Q2-2025 | $250.72M ▼ | $492.13M ▼ | $147.21M ▲ | $344.92M ▼ |
| Q1-2025 | $284.5M ▼ | $527.85M ▼ | $141.6M ▼ | $386.25M ▼ |
| Q4-2024 | $482.18M ▼ | $576.8M ▼ | $175.25M ▲ | $401.55M ▼ |
| Q3-2024 | $518.45M | $609.72M | $110.58M | $499.14M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-54.89M ▼ | $-58.31M ▼ | $61.95M ▲ | $3.44M ▲ | $6.57M ▲ | $-58.55M ▼ |
| Q2-2025 | $-50.34M ▼ | $-22.45M ▲ | $-39.95M ▲ | $1.6M ▼ | $-60.91M ▲ | $-22.58M ▲ |
| Q1-2025 | $-26.14M ▲ | $-57.25M ▼ | $-222.39M ▼ | $3.09M ▲ | $-278.06M ▼ | $-57.25M ▼ |
| Q4-2024 | $-111.33M ▼ | $-42.8M ▼ | $25M ▼ | $2.96M ▼ | $-11.8M ▼ | $-42.8M ▼ |
| Q3-2024 | $-42.57M | $-21.39M | $44.96M | $245.98M | $267.65M | $-21.42M |
Revenue by Products
| Product | Q1-2025 |
|---|---|
 Reportable Segment | $10.00M ▲ |
CEO
Saurabh Saha
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 16
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
B. Riley Securities
Buy
Guggenheim
Buy
Chardan Capital
Buy
Oppenheimer
Outperform
Wells Fargo
Overweight
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
MEDICXI VENTURES MANAGEMENT (JERSEY) LTD
Shares:19.96M
Value:$440.99M
AVORO CAPITAL ADVISORS LLC
Shares:10.81M
Value:$238.75M
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:10.04M
Value:$221.67M
Summary
Showing Top 3 of 131